A5017623567- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Genetic and Kidney Cyst Diseases
- Inflammatory Biomarkers in Disease Prognosis
- Ferroptosis and cancer prognosis
- Congenital Anomalies and Fetal Surgery
- Lung Cancer Treatments and Mutations
First Affiliated Hospital of Nanchang University
2022-2025
Nanchang University
2022-2025
First Affiliated Hospital of Jiangxi Medical College
2024
Unresectable hepatocellular carcinoma (u-HCC) still accounts for the majority of newly diagnosed HCC which with poor prognosis. In era systemic therapy, combination therapy programmed cell death protein-1 (PD-1) inhibitors and tyrosine kinase (TKIs) has become mainstream. Hepatic arterial infusion chemotherapy (HAIC) as a local treatment also shown strong anti-tumor effect. This study aimed to investigate efficacy safety HAIC, PD-1 plus TKIs u-HCC.This retrospective included patients...
Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was evaluate the safety and efficacy hepatectomy after conversion how it differed from those who undergoing direct hepatectomy. From January 2018 April 2022, 745 underwent for HCC were enrolled. Among them, 41 therapy. A demographically clinically comparable cohort created remaining in a 1:1 ratio using propensity score matching. median duration 108...
Hepatocellular carcinoma (HCC) frequently recurs after surgical treatment, necessitating effective postoperative recurrence management for improved long-term patient outcomes. Currently, no standardized treatment approach exists recurrent unresectable HCC. This study aims to investigate the safety and efficacy of combining tyrosine kinase inhibitors (TKIs) programmed cell death protein-1 (PD-1) with hepatic arterial infusion chemotherapy (HAIC) or transarterial chemoembolization (TACE) in A...
This study aimed to assess the prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with unresectable hepatocellular carcinoma (u-HCC) treated hepatic artery infusion chemotherapy (HAIC) combined lenvatinib and camrelizumab.We conducted a retrospective cohort involving diagnosed u-HCC who underwent HAIC camrelizumab. Patients were stratified into two cohorts using median NLR as cutoff point. We then assessed treatment response, overall survival (OS), progression-free...
Combination therapy is the primary treatment for unresectable hepatocellular carcinoma (u-HCC). The hepatic functional reserve also critical in of HCC. In this study, u-HCC was treated with combined arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and programmed cell death protein-1 (PD-1) to analyze therapeutic response, progression-free survival (PFS), safety.
This study aimed to assess the prognostic significance of alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (u-HCC) who underwent hepatic artery infusion chemotherapy (HAIC) combined lenvatinib and camrelizumab.
Abstract Background/Aim: Recently, an increase in the number of asymptomatic rare benign liver tumors (BLTs) has been reported during health check-ups. It is difficult to determine nature partial BLTs and not easy distinguish from malignant tumors. This study aimed analysis clinical features, diagnosis, treatment reduce misdiagnosis provide reference for practice. Methods: From January 2012 2021, we treated 112 by hepatectomy, including 54 focal nodular hyperplasia, 14 hepatocellular...